Table 4 Participant characteristics and study details of included studies
Author (Date) | Study Design | Population: n enrolled, n completed/relevant (gender), mean age (range), location | Disease (Severity/Stage) | Timing of Intervention Delivery | Setting |
|---|---|---|---|---|---|
Betker, et al. [49] | Single subject case-study | 3, 1 (male), 20 (NS), Canada | Cerebellar tumour (Severe ataxia) | NS | Hospital |
Feasibility study | 9, 7 (2 male), 64.6 (53–73), USA | Lung cancer (Stage 1A = 1, 1B = 1, 2A = 1, 2B = 2, 3A = 2) | Pre-surgery, post-surgery, weekly follow-ups for 16 weeks. | Home | |
House, et al. [47] | Feasibility study | 12, 6 (0 male), 57.8 (22–78), USA | Breast cancer (NS) | 9.5 years post-surgery | Clinical Laboratory |
Jahn, et al. [26] | Exploratory study with qualitative evaluation. | 11, 7 (5 male), 56.6 (47–70), Germany | 1 = Rectal cancer, 1 = Brain metastases & breast cancer, 1 = Oesophageal cancer, 1 = Tongue cancer, 3 = Lung cancer (NS) | Receiving treatment for current cancer diagnosis | Hospital |
Sajid, et al. [46] | Randomised three-arm pilot study | 31, 19 up to 6 weeks (19 male), 13 after 6 weeks. Wii Group = 8 (n-3 after 6 weeks), 77.5 (70–87). EXCAP group = 6 (n-1 after 6 weeks), 75.7 (67–93). Usual Care = 5 (n-2 after 6 weeks), 71.8 (67–80). USA | Prostate cancer (NS) | 62 month after initial ADT | Home |
Tsuda, et al. [48] | Feasibility study | 16, 9 (6 male), 67.4 (61–76), Japan | 6 = Leukaemia, 3 = Lymphoma (NS) | Receiving treatment for current cancer diagnosis | Hospital |
Yoon, et al. [20] | Controlled study | 47, 40 (17 male). IREX group = 20 (9 male), 48.6 (NS). COT = 20 (8 male), 50 (NS). South Korea | Brain tumour (NS) | 9 month after diagnosis | NS |